-->

Tag: FDA breakthrough lung cancer therapy

Home / FDA breakthrough lung cancer therapy

Categories

Neoadjuvant/ adjuvant pembrolizumab is approved by the FDA for resectable non-small cell lung cancer

Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post...
fda-breakthrough-lung-cancer-therapy

Scan the code